$FEMY
FEMASYS INC

2023 Q4 Form 10-Q Financial Statement

#000114036123053090 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $213.1K $244.4K
YoY Change -9.02% -29.67%
Cost Of Revenue $78.29K $86.19K
YoY Change -8.39% -34.43%
Gross Profit $134.8K $158.2K
YoY Change -9.38% -26.77%
Gross Profit Margin 63.26% 64.73%
Selling, General & Admin $2.421M $2.041M
YoY Change 38.93% 37.42%
% of Gross Profit 1795.93% 1290.53%
Research & Development $2.071M $2.073M
YoY Change 62.88% 25.77%
% of Gross Profit 1536.32% 1310.47%
Depreciation & Amortization $91.79K $131.7K
YoY Change -31.88% -5.67%
% of Gross Profit 68.08% 83.26%
Operating Expenses $4.584M $4.239M
YoY Change 45.57% 29.52%
Operating Profit -$4.450M -$4.081M
YoY Change 48.3% 33.5%
Interest Expense $43.40K $8.033K
YoY Change -62.18% 33.77%
% of Operating Profit
Other Income/Expense, Net $0.00 $84.36K
YoY Change -100.0% 13.47%
Pretax Income -$4.406M -$3.997M
YoY Change 52.57% 34.0%
Income Tax $4.340K $0.00
% Of Pretax Income
Net Earnings -$4.410M -$3.997M
YoY Change 52.39% 34.0%
Net Earnings / Revenue -2069.57% -1635.66%
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$0.21 -$0.26
COMMON SHARES
Basic Shares Outstanding 21.65M 15.07M
Diluted Shares Outstanding 15.09M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.72M $8.692M
YoY Change 67.54% -45.69%
Cash & Equivalents $21.72M $8.692M
Short-Term Investments
Other Short-Term Assets $695.9K $826.4K
YoY Change 6.18% 8.65%
Inventory $667.1K $602.7K
Prepaid Expenses
Receivables $98.91K $103.6K
Other Receivables $0.00 $0.00
Total Short-Term Assets $23.18M $10.23M
YoY Change 64.02% -40.87%
LONG-TERM ASSETS
Property, Plant & Equipment $3.491M $1.161M
YoY Change 135.41% -24.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.087M $937.0K
YoY Change 13.4% 18.66%
Total Long-Term Assets $4.578M $4.629M
YoY Change 65.62% 68.95%
TOTAL ASSETS
Total Short-Term Assets $23.18M $10.23M
Total Long-Term Assets $4.578M $4.629M
Total Assets $27.76M $14.85M
YoY Change 64.28% -25.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.138M $851.9K
YoY Change 122.77% 103.26%
Accrued Expenses $1.444M $569.4K
YoY Change 216.24% -12.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $406.6K $693.6K
YoY Change -21.06% 4.02%
Total Short-Term Liabilities $3.054M $2.187M
YoY Change 99.9% 20.98%
LONG-TERM LIABILITIES
Long-Term Debt $6.294M $2.169M
YoY Change 21923.27% 1773.52%
Other Long-Term Liabilities $54.94K $54.02K
YoY Change -43.16% -46.94%
Total Long-Term Liabilities $6.349M $2.223M
YoY Change 4969.54% 921.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.054M $2.187M
Total Long-Term Liabilities $6.349M $2.223M
Total Liabilities $9.403M $4.410M
YoY Change 468.84% 117.74%
SHAREHOLDERS EQUITY
Retained Earnings -$108.4M -$104.0M
YoY Change 15.13% 13.95%
Common Stock $21.78K $16.11K
YoY Change 81.66% 35.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.35M $10.44M
YoY Change
Total Liabilities & Shareholders Equity $27.76M $14.85M
YoY Change 64.28% -25.85%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$4.410M -$3.997M
YoY Change 52.39% 34.0%
Depreciation, Depletion And Amortization $91.79K $131.7K
YoY Change -31.88% -5.67%
Cash From Operating Activities -$3.036M -$2.855M
YoY Change 5.86% 4.56%
INVESTING ACTIVITIES
Capital Expenditures $44.90K $29.02K
YoY Change -52.17% -256.53%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$44.90K -$29.02K
YoY Change -52.17% 56.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.10M 874.1K
YoY Change -19751.64% -341.43%
NET CHANGE
Cash From Operating Activities -3.036M -2.855M
Cash From Investing Activities -44.90K -29.02K
Cash From Financing Activities 16.10M 874.1K
Net Change In Cash 13.02M -2.010M
YoY Change -527.89% -35.4%
FREE CASH FLOW
Cash From Operating Activities -$3.036M -$2.855M
Capital Expenditures $44.90K $29.02K
Free Cash Flow -$3.081M -$2.884M
YoY Change 4.02% 6.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15992869
CY2023Q3 us-gaap Gross Profit
GrossProfit
158175
CY2022Q3 us-gaap Gross Profit
GrossProfit
216005
us-gaap Gross Profit
GrossProfit
557084
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
92392
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Suwanee
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21649623
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16110092
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11986927
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11869704
us-gaap Gross Profit
GrossProfit
615495
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
80373
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
232133
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
109572
CY2023Q3 us-gaap Interest Expense
InterestExpense
8033
CY2022Q3 us-gaap Interest Expense
InterestExpense
6005
us-gaap Interest Expense
InterestExpense
9903
us-gaap Interest Expense
InterestExpense
9622
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12876173
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10443602
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15242519
femy Stock Issued During Period Value Issuance Of Common Stock And Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants
3345996
femy Stock Issued During Period Value At The Market Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingNetOfIssuanceCosts
3368
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1697
femy Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
188
us-gaap Net Income Loss
NetIncomeLoss
-9836670
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10443602
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20937928
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51762
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
4972
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
3800
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-44538
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Share Based Compensation
ShareBasedCompensation
626529
us-gaap Share Based Compensation
ShareBasedCompensation
158288
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26086
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
98872
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
170917
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
138666
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-313154
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-359307
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
341119
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-49449
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
112728
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
45828
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-304004
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-290104
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-15770
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-30696
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8244566
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7864086
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99018
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
313598
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-313598
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3899813
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
547764
femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
188
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1697
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
16151
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
232845
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
FEMY
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001339005
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 femy Lease Extended Date
LeaseExtendedDate
2029-04-30
dei Entity File Number
EntityFileNumber
001-40492
dei Entity Registrant Name
EntityRegistrantName
Femasys Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3713499
dei Entity Address Address Line1
EntityAddressAddressLine1
3950 Johns Creek Court
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30024
dei City Area Code
CityAreaCode
770
dei Local Phone Number
LocalPhoneNumber
500-3910
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
283334
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
141298
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
22
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
22
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
504359
CY2023Q3 femy Stock Issued During Period Value Exercise Of Common Warrants
StockIssuedDuringPeriodValueExerciseOfCommonWarrants
1059975
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3996905
femy Stock Issued During Period Value Exercise Of Common Warrants
StockIssuedDuringPeriodValueExerciseOfCommonWarrants
1059975
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
626529
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2982843
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
18006847
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26332382
femy Expiration Of Warrant
ExpirationOfWarrant
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16151
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
158288
us-gaap Net Income Loss
NetIncomeLoss
-8499974
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
18006847
us-gaap Net Income Loss
NetIncomeLoss
-9836670
us-gaap Net Income Loss
NetIncomeLoss
-8499974
us-gaap Depreciation
Depreciation
388777
us-gaap Depreciation
Depreciation
407146
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2906
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19334
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
274158
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
249972
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-99018
femy Proceeds From Exercise Of Common Stock Warrants
ProceedsFromExerciseOfCommonStockWarrants
1059975
femy Proceeds From Exercise Of Common Stock Warrants
ProceedsFromExerciseOfCommonStockWarrants
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3373
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
327006
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
365926
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16193
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
17075
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4074083
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-599695
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4269501
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8777379
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12961936
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24783029
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8692435
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16005650
us-gaap Interest Paid Net
InterestPaidNet
9903
us-gaap Interest Paid Net
InterestPaidNet
9622
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4550
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5050
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2496968
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
femy Property And Equipment Costs Included In Accounts Payable
PropertyAndEquipmentCostsIncludedInAccountsPayable
0
femy Property And Equipment Costs Included In Accounts Payable
PropertyAndEquipmentCostsIncludedInAccountsPayable
23037
femy Commissions And Deferred Offering Costs Relating To Proceeds From Issuance Of Common Stock
CommissionsAndDeferredOfferingCostsRelatingToProceedsFromIssuanceOfCommonStock
6163
femy Commissions And Deferred Offering Costs Relating To Proceeds From Issuance Of Common Stock
CommissionsAndDeferredOfferingCostsRelatingToProceedsFromIssuanceOfCommonStock
0
femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
283334
femy Prepaid Insurance Financed With Promissory Note
PrepaidInsuranceFinancedWithPromissoryNote
280577
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11197
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
569442
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
456714
CY2023Q3 femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
2468809
CY2022Q3 femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
0
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8692435
us-gaap Net Income Loss
NetIncomeLoss
-9836670
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
361569
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
244498
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
51358
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
100453
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
189741
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
91772
CY2023Q3 us-gaap Inventory Net
InventoryNet
602668
CY2022Q4 us-gaap Inventory Net
InventoryNet
436723
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3560
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2103
CY2023Q3 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
313029
CY2022Q4 femy Accrued Clinical Trial Cost
AccruedClinicalTrialCost
333440
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
155192
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
85191
CY2023Q3 femy Franchise Taxes
FranchiseTaxes
0
CY2022Q4 femy Franchise Taxes
FranchiseTaxes
26886
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
90000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
0
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11221
CY2022Q4 femy Clinical Holdback Liability
ClinicalHoldbackLiability
141864
femy Clinical Holdback Retained
ClinicalHoldbackRetained
4529
femy Clinical Holdback Paid
ClinicalHoldbackPaid
20299
CY2023Q3 femy Clinical Holdback Liability
ClinicalHoldbackLiability
126094
CY2023Q3 femy Clinical Holdback Current
ClinicalHoldbackCurrent
72075
CY2023Q3 femy Clinical Holdback Noncurrent
ClinicalHoldbackNoncurrent
54019
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2022Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
femy Percentage Of Restocking Fee
PercentageOfRestockingFee
0.30
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
3321025
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P63M
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2496968
CY2023Q3 femy Proceeds From Exercise Of Common Stock Warrants
ProceedsFromExerciseOfCommonStockWarrants
1059975
femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
2468809
femy Incremental Common Shares Attributable To Dilutive Effect Of Pre Funded Warrants Common Warrants And Placement Agent Warrants
IncrementalCommonSharesAttributableToDilutiveEffectOfPreFundedWarrantsCommonWarrantsAndPlacementAgentWarrants
0
CY2023Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2022Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
233460
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4931540
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Placement Agent Fees Expenses And Offering Expenses
PlacementAgentFeesExpensesAndOfferingExpenses
547764
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15992869
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
504359
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51762
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
626529
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
158288
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
864904
femy Share Based Compensation Expense To Be Recognized Upon Achieving Certain Performance Condition
ShareBasedCompensationExpenseToBeRecognizedUponAchievingCertainPerformanceCondition
155222
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
709682
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1318000
CY2023Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3899813
CY2023Q2 femy Payments Of Equity Issuance Costs
PaymentsOfEquityIssuanceCosts
547764
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1133480
CY2023Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3352049
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3996905
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3996905
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2982843
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2982843
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9836670
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9836670
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8499974
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8499974
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15093147
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15093147
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11813610
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11813610
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13369462
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13369462
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11810289
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11810289
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2229271
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1071573
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2229271
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1071573
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1305033
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4931540
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1305033

Files In Submission

Name View Source Status
0001140361-23-053090-index-headers.html Edgar Link pending
0001140361-23-053090-index.html Edgar Link pending
0001140361-23-053090.txt Edgar Link pending
0001140361-23-053090-xbrl.zip Edgar Link pending
ef20012433_10q.htm Edgar Link pending
ef20012433_ex31-1.htm Edgar Link pending
ef20012433_ex31-2.htm Edgar Link pending
ef20012433_ex32-1.htm Edgar Link pending
ef20012433_ex32-2.htm Edgar Link pending
femy-20230930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
femy-20230930_lab.xml Edgar Link unprocessable
femy-20230930_pre.xml Edgar Link unprocessable
femy-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ef20012433_10q_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
femy-20230930_cal.xml Edgar Link unprocessable